Clinical characteristics of children with multisystemic inflammatory syndrome associated with COVID-19

Basit Öğe Kaydı
dc.contributor.authorAlpcan, Aysegul
dc.contributor.authorTursun, Serkan
dc.contributor.authorKandur, Yasar
dc.date.accessioned2025-01-21T16:36:35Z
dc.date.available2025-01-21T16:36:35Z
dc.date.issued2022
dc.departmentKırıkkale Üniversitesi
dc.description.abstractAim: Coronavirus disease 2019 (COVID-19) has become a public health threat to people all over the world in 2020 and 2021. The Centers for Disease Control and Prevention (CDC) and WHO (World Health Organization) have named a novel disease multisystem inflammatory syndrome in children (MIS-C). Herein we aimed to present a group of pediatric patients with MIS-C, who were followed up in our clinic. Material and Methods: We retrospectively reviewed the medical records of patients who were followed up at our University Hospital with the diagnosis of MIS-C between January 2021 and May 2021. Results: The mean age of 9 patients was 87.4 +/- 17.8 years (range 6-161 months); six of the patients were male. All patients had fever at admission. The duration of the fever was between 3 and 7 days. Four patients (44.4%) had terminal ileitis on ultrasonic examination. The laboratory tests of the patients revealed leukocytosis in 4 (44.4%) patients, anemia in 5 (55.5%) patients, thrombocytopenia in 1 (11.1%) patient, and a high CRP level in 8 (88.8%) patients. All patients had high sedimentation rates and procalcitonin levels. One (11.1%) patient was operated on for terminal ileitis. All patients were treated with steroids (1-2 mg/kg prednisolone) and IVIG (2gr/kg). Patients who needed ICU admission were also treated with vasoactive drug infusion (intravenous dopamine). Discussion: There is a need for increased awareness among pediatricians that MIS-C should come to mind, especially in patients with long-lasting fever and signs and symptoms that resemble Kawasaki disease.
dc.identifier.doi10.4328/ACAM.20804
dc.identifier.endpage9
dc.identifier.issn2667-663X
dc.identifier.issue1
dc.identifier.startpage6
dc.identifier.urihttps://doi.org/10.4328/ACAM.20804
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24345
dc.identifier.volume13
dc.identifier.wosWOS:000729255800001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherBayrakol Medical Publisher
dc.relation.ispartofAnnals of Clinical and Analytical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectMultisystem Inflammatory Syndrome; Children; Hyperinflammation; Steroid; Intensive Care; COVID-19
dc.titleClinical characteristics of children with multisystemic inflammatory syndrome associated with COVID-19
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu